Contemporary real-world treatment in metastatic hormone-sensitive prostate cancer: US, four European countries, and UK.

In terms of ethnicity, patients in treatment cohorts were generally Caucasian (60%–70%), Black/African American (20%–25%), or Hispanic/Latin American (5%–10%), with the remainder Asian or “Other.” The NSAA + ADT cohort featured the greatest proportion of Caucasians and the docetaxel + ADT cohort the smallest, though the difference in ethnic composition did not reach statistical significance.

also in 111,027 other papers